

1992 INDEX

A

- Ablation of endometrium, Mar./Apr. 57-59
 - with resectoscope, Mar./Apr. 59
- Anal reflexes, May/June 126
- Analgesia: for electrosurgery of cervical intraepithelial tumors, July/Aug. 193-194
- Anogenital papillomavirus: types and biology, July/Aug. 167-168
- Aspiration of breast lesions (*see* Breast lesions, aspiration)

B

- Baumrucker resectoscope, Mar./Apr. 53
- Bethesda system
 - benign cellular changes, Sept./Oct. 226-227
 - categorization, general, Sept./Oct. 226
 - CIN in atypical smears, Sept./Oct. 227
 - diagnosis, descriptive, Sept./Oct. 226-235
 - on dysplasia, mild, Sept./Oct. 232
 - endocervical cells, Sept./Oct. 233-234
 - endometrial cells, Sept./Oct. 234-235
 - epithelial cell abnormalities, Sept./Oct. 227-233
 - atypical squamous cells of undetermined significance, Sept./Oct. 227-228
 - CIN-1, regression, persistence and progression, Sept./Oct. 231
 - format of report, Sept./Oct. 224-235
 - glandular cell abnormalities, Sept./Oct. 233-235
 - atypical glandular cells of undetermined significance, Sept./Oct. 233, Sept./Oct. 234
 - improving communication among cytopathologists, clinicians and patients, Sept./Oct. 223
 - initiation of appropriate action, Sept./Oct. 223
 - koilocytes in, Sept./Oct. 230
 - objectives of, Sept./Oct. 221-223
 - papilloma virus, regression, persistence and progression, Sept./Oct. 231
 - pathology rate in smears using brush vs. spatula or cotton-tipped applicator, Sept./Oct. 225
 - to report cervicovaginal cytology diagnoses, Sept./Oct. 221-223
 - specimen adequacy, Sept./Oct. 224-226
 - squamous intraepithelial lesions, Sept./Oct. 228-233
 - high-grade, Sept./Oct. 229, 232-233
 - high-grade, features, Sept./Oct. 233
 - low-grade, Sept./Oct. 229-232
 - low-grade, features of, Sept./Oct. 233
 - terminology
 - in cervical cancer precursors, Sept./Oct. 236-238
 - impact on clinical practice, Sept./Oct. 235-236
- Biopsy
 - of breast lesions, open, Jan./Feb. 19-20
 - in hysteroscopic surgery with resectoscope, Mar./Apr. 56
- Breast
 - anatomy, Jan./Feb. 11

- cancer, Jan./Feb. 20-32
 - diagnosis, Jan./Feb. 23
 - evaluation, Jan./Feb. 23-24
 - medical legal issues in, Jan./Feb. 32
 - metastatic, treatment, Jan./Feb. 31-32
 - recurrent, treatment, Jan./Feb. 31-32
 - staging, Jan./Feb. 23
 - staging system, TNM, Jan./Feb. 34
 - surgical options, Jan./Feb. 25-27
 - treatment, adjuvant, Jan./Feb. 27-28
 - treatment options, Jan./Feb. 24-25
 - disease, Jan./Feb. 5-37
 - abstract, Jan./Feb. 5
 - in brief, Jan./Feb. 5-7
 - during pregnancy, Jan./Feb. 11-12
 - fibrocystic changes, Jan./Feb. 12-13
 - fibrocystic disease as precancerous, Jan./Feb. 33
 - lesions
 - aspiration, cyst, Jan./Feb. 16
 - aspiration, fine-needle, Jan./Feb. 16-17
 - biopsy, open, Jan./Feb. 19-20
 - diagnosis, Jan./Feb. 14-20
 - mammography of, Jan./Feb. 17
 - resolution of, Jan./Feb. 14-20
 - ultrasound of, Jan./Feb. 17
 - physiology, Jan./Feb. 11
 - tumors, benign, Jan./Feb. 13-14
- Burn**
- due to electrosurgery, July/Aug. 182
 - of myometrium due to electrode, Mar./Apr. 60

C

- Cancer
 - breast (*see* Breast cancer)
 - cervix (*see* Cervix, cancer)
 - gynecologic (*see* Gynecologic cancer)
 - hysteroscopic surgery with resectoscope and, Mar./Apr. 63
- Carcinoma
 - cervix
 - staging, Nov./Dec. 262-265
 - staging system, first, Nov./Dec. 252
 - fallopian tubes, staging, Nov./Dec. 262
 - ovaries
 - stage grouping, Nov./Dec. 259
 - staging, Nov./Dec. 266
 - uterus, corpus
 - staging, Nov./Dec. 265-266
 - surgical staging, Nov./Dec. 261
 - vulva (*see* Vulva, carcinoma)
- Catheters: urodynamic, in incontinence, May/June 141
- Cervical cytology
 - Bethesda system (*see* Bethesda system)
 - cytologic method low sensitivity, Sept./Oct. 217-219
 - Papanicolaou smear (*see* Papanicolaou smear)

Cervical cytology (*cont.*)

terminology

of Bethesda system (*see* Bethesda system, terminology)

nonuniform, of cervical smear report, Sept./Oct. 219-220

Cervicography: in cervical cancer, Sept./Oct. 237

Cervicovaginal cytology, Sept./Oct. 210-241

abstract, Sept./Oct. 210

in brief, Sept./Oct. 211-213

screening devices, automated, Sept./Oct. 238

terminology, new, Sept./Oct. 210

Cervix

cancer

cervicography in, Sept./Oct. 237

DNA hybridization in, Sept./Oct. 237-238

incidence, Sept./Oct. 216

loop electrode excision procedure in, Sept./Oct. 238

precursors, and Bethesda system terminology, Sept./Oct. 236-238

screening pitfalls, Sept./Oct. 216-221

screening pitfalls, cytologic method low sensitivity, Sept./Oct. 217-219

screening pitfalls, inability to reach women at risk, Sept./Oct. 217

screening pitfalls, inadequate communication among cytopathologists, clinicians and patients, Sept./Oct. 220-221

screening pitfalls, inappropriate action on abnormal smear, Sept./Oct. 221

screening pitfalls, negative cervical smears in cervical cancer, Sept./Oct. 218

screening pitfalls, nonuniform terminology of cervical smear report, Sept./Oct. 219

screening pitfalls, percentage of women with no recent cervical smears, Sept./Oct. 217

cancer precursors, July/Aug. 171-173

natural history, July/Aug. 171

carcinoma

staging, Nov./Dec. 262-265

staging system, first, Nov./Dec. 252

epithelial cell abnormalities (*see* Bethesda system, epithelial cell abnormalities)

tumor, intraepithelial, July/Aug. 158-204

abstract, July/Aug. 158

in brief, July/Aug. 158-161

colposcopy of, cancer development after, July/Aug. 174

conservative management protocols, problems with, July/Aug. 174

conservative treatment, cancer after, July/Aug. 174

cryosurgery for conservative treatment, July/Aug. 172-173

electrocautery for, July/Aug. 172

electrofulguration for, July/Aug. 172

epidemiologic studies, July/Aug. 164-165

etiology, July/Aug. 163-164

excisional protocols, rationale for, July/Aug. 174

high-grade, histologic criteria for, July/Aug. 170-171

large loop excision and transformation zone (*see below*)

laser ablation for, July/Aug. 173

low-grade, histologic criteria for, July/Aug. 170

management conservative protocols for, development of, July/Aug. 171-172

papillomavirus in (*see* Papillomavirus)

pathogenesis, July/Aug. 164-169

pathology, July/Aug. 169-170

tumor, intraepithelial, large loop excision of transformation zone, July/Aug. 190-203

advantages of, July/Aug. 174-175

alternatives to, therapeutic, July/Aug. 192

analgesia for, July/Aug. 193-194

colposcopy couch, July/Aug. 193

Cuso speculum for, July/Aug. 193

dental syringe system for, July/Aug. 191

desiccation, diagrammatic representation, July/Aug. 195

diagrammatic representation, July/Aug. 195

efficacy of, July/Aug. 203

electrosurgery for, July/Aug. 179-189

fulguration, diagrammatic representation, July/Aug. 195

instrumentation selection, July/Aug. 195-200

loop designs for, July/Aug. 191

management of biopsy, July/Aug. 201-203

management of cervix, July/Aug. 200-201

management of patient, July/Aug. 203

management protocols after, July/Aug. 200-203

Monse's solution, July/Aug. 202

power settings for, July/Aug. 195-200

preliminary colposcopic exam, July/Aug. 191-192

rollerball for fulgurative and coagulative diathermy of wound, July/Aug. 201

in suspicion of glandular abnormality, July/Aug. 200

in suspicion of invasive disease, July/Aug. 200

technique, July/Aug. 192-203

transformation zone, original and congenital, July/Aug. 200

Clitoral reflexes, May/June 126

Colposcopy

in cervical intraepithelial tumors, July/Aug. 191-192

cancer after, July/Aug. 174

couch, July/Aug. 193

Cough urethral closure pressure profiles, May/June 143

Cryosurgery: in cervical intraepithelial tumors, July/Aug. 172-173

Cuso speculum: in electrosurgery of cervical intraepithelial tumors, July/Aug. 193

Cyst aspiration: of breast lesions, Jan./Feb. 16

Cystometer: manometric water, May/June 132

Cystometry

detrusor incontinence during, May/June 117

in incontinence, May/June 131-135

standing incremental, sensitivity, specificity and predictive values of, May/June 133

variables, May/June 131

Cystoscopy: in incontinence, May/June 130-131

Cytology, cervicovaginal (*see* Cervicovaginal cytology)

D

- Dental syringe system: for electrosurgery of cervical intraepithelial tumors, July/Aug. 191
- Dermatomes: lower extremity sensory, May/June 127
- Desiccation: and electrosurgery, July/Aug. 186
- Detrusor instability
 - during cystometry, May/June 117
 - urethrocystometry of, May/June 140
 - uroflowmetry in, normal, May/June 128
- Diapers: incontinence, May/June 116
- Diathermy: rollerball for, in electrosurgery of cervical intraepithelial tumors, July/Aug. 201
- DNA hybridization: in cervical cancer, Sept./Oct. 237-238
- Dysplasia: and Bethesda system, Sept./Oct. 232

E

- Electrocautery: in cervical intraepithelial tumors, July/Aug. 172
- Electrode(s)
 - for resectoscope, Mar./Apr. 52
 - roller ball
 - 2 mm, Mar./Apr. 58
 - myometrial burn due to, Mar./Apr. 60
- Electrofulguration: in cervical intraepithelial tumors, July/Aug. 172
- Electrosurgery, July/Aug. 179-189
 - blended current, July/Aug. 186
 - burn due to indifferent electrode, July/Aug. 182
 - coagulation current, July/Aug. 184-186
 - crest factors, July/Aug. 186
 - cutting current, July/Aug. 183-184
 - desiccation, July/Aug. 186
 - frequency of current, July/Aug. 181
 - glossary, July/Aug. 189
 - history of, July/Aug. 180-181
 - for large loop excision of transformation zone of intraepithelial cervical tumors, July/Aug. 179-189
 - monopolar current, July/Aug. 181-183
 - radiofrequency, July/Aug. 182
 - spark-gap type, July/Aug. 183
 - terminology, July/Aug. 180
 - unipolar current passing from electrode through patient's body, July/Aug. 182
 - unit safety, July/Aug. 187-188
 - units for resectoscope, Mar./Apr. 54
 - wattage having different voltages, July/Aug. 185
 - waveforms generated by electrosurgical unit, July/Aug. 185
- Endocervical cells: and Bethesda system, Sept./Oct. 233-234
- Endometrium
 - ablation, Mar./Apr. 57-59
 - with resectoscope, Mar./Apr. 59
 - cells, and Bethesda system, Sept./Oct. 234-235
 - removal of, Mar./Apr. 57
 - resection, Mar./Apr. 57-59
 - with resectoscope, Mar./Apr. 59
- Endoscopy: in incontinence, May/June 130-131

Extremities: lower extremity sensory dermatomes, May/June 127

F

- Fallopian tubes: carcinoma, staging, Nov./Dec. 262
- Fibrocystic
 - changes in breast, Jan./Feb. 12-13
 - disease as precancerous, Jan./Feb. 33
- Fluids
 - bags for hysteroscopic surgery with resectoscope, Mar./Apr. 56
 - choice of, in hysteroscopic surgery with resectoscope, Mar./Apr. 55
- Fulguration: in electrosurgery of cervical intraepithelial tumors, July/Aug. 195

G

- Genomic organization: of papillomavirus, July/Aug. 166
- Gestational trophoblastic tumors: staging, Nov./Dec. 262, 266
- Glycine: absorption in intrauterine surgery, Mar./Apr. 61
- Gynecologic cancer
 - classification, history of, Nov./Dec. 251-261
 - staging, Nov./Dec. 248-268
 - abstract, Nov./Dec. 248
 - in brief, Nov./Dec. 248-249
 - history of, Nov./Dec. 251-261

H

- Hybridization: DNA, in cervical cancer precursors, Sept./Oct. 237-238
- Hysteroscope: operating, conversion of resectoscope to, Mar./Apr. 53
- Hysteroscopic surgery with resectoscope, Mar./Apr. 48-67
 - abstract, Mar./Apr. 48-67
 - for biopsy, Mar./Apr. 56
 - bleeding after, late, Mar./Apr. 63
 - in brief, Mar./Apr. 48-49
 - cancer after, Mar./Apr. 63
 - complications
 - immediate, Mar./Apr. 60-63
 - late, Mar./Apr. 63
 - distension
 - media, Mar./Apr. 55-56
 - pressure, Mar./Apr. 55-56
 - fluid bags for, Mar./Apr. 56
 - fluids, choice of, Mar./Apr. 55
 - infection after, Mar./Apr. 63
 - postoperative drugs, Mar./Apr. 60
 - pregnancy and, Mar./Apr. 63
 - preparation of patient, Mar./Apr. 59
 - selection of patient, Mar./Apr. 59-60
 - training for, Mar./Apr. 63-64
- Hysteroscopy
 - accessories, Mar./Apr. 54
 - bridge, Mar./Apr. 54
 - operative, complications, Mar./Apr. 60

I

- Incontinence, May/June 109–151
 abstract, May/June 109–110
 in brief, May/June 110–113
 cystometry in, May/June 131–135
 cystoscopy in, May/June 130–131
 definitions, May/June 116–118
 diapers, May/June 116
 endoscopy in, May/June 130–131
 evaluation
 initial office, May/June 120–138
 urodynamic complex, May/June 138–146
 leak point pressure, May/June 143–144
 measures of, simple objective, May/June 135–138
 micturition neurologic control, May/June 125–127
 multichannel urodynamics, symptoms and findings
 in, May/June 123
 neurologic examination, May/June 125–127
 pad test, modified 20-minute, May/June 137
 pads, May/June 116
 pathophysiology, May/June 118–120
 physical examination, May/June 123–125
 symptoms
 and findings in multichannel urodynamics, May/June 123
 sensitivity, specificity and predictive values, May/June 123
 urethra (*see under* Urethra)
 urethrocystometry in, May/June 139–141
 urethroscopy in, May/June 130–131
 urodynamic catheters, May/June 141
 urodynamic evaluation, complex, May/June 138–146
 urodynamic studies, multichannel, May/June 138–139
 uroflowmetry in, May/June 128–129
 urogynecologic history, May/June 120–123
 questionnaire for, May/June 121–122
 videocystourethrography in, May/June 146
 voiding pressure studies, May/June 144–146
 Infection: after hysteroscopic surgery with resectoscope, Mar./Apr. 63
 Intrauterine (*see* Uterus)

K

- Koilocytes: and Bethesda system, Sept./Oct. 230

L

- Laser
 for ablation of cervical intraepithelial tumors, July/Aug. 173
 Nd:YAG fiber, Mar./Apr. 58
 Legal medical issues: in breast cancer, Jan./Feb. 32
 Loop electrode excision procedure: and cervical cancer, Sept./Oct. 238

M

- Mammography: of breast lesions, Jan./Feb. 17
 Manometric water cystometer, May/June 132

- Medical legal issues: in breast cancer, Jan./Feb. 32
 Metastases: of breast cancer, treatment, Jan./Feb. 31–32
 Micturition: neurological control in incontinence evaluation, May/June 125–127
 Monsel's solution, July/Aug. 202
 Myoma of uterus: resection, Mar./Apr. 56–57
 Myometrium
 burn due to electrode, Mar./Apr. 60
 removal of, Mar./Apr. 57

N

- Nd:YAG laser fiber, Mar./Apr. 58
 Neoplasm (*see* Tumor)

O

- Ovaries, carcinoma
 stage grouping, Nov./Dec. 259
 staging, Nov./Dec. 266

P

- Pad test: modified 20-minute, May/June 137
 Pads: incontinence, May/June 116
 Papanicolaou smear
 pathology rate in smears using brush vs. spatula or cotton-tipped applicator, Sept./Oct. 225
 reporting systems, comparison of, Sept./Oct. 219
 Papillomavirus, July/Aug. 165–169
 anogenital, types and biology, July/Aug. 167–168
 associated disease, clinical spectrum of, July/Aug. 168–169
 Bethesda system and, regression, persistence and progression, Sept./Oct. 231
 genomic organization of, July/Aug. 166
 oncogenic risk groups, July/Aug. 167
 structure of, July/Aug. 165–167
 Polyps: of uterus, resection, Mar./Apr. 56–57
 Pregnancy
 breast disease during, Jan./Feb. 11–12
 hysteroscopic surgery with resectoscope and, Mar./Apr. 63

R

- Reflexes
 anal, May/June 126
 clitoral, May/June 126
 Resectoscope, Mar./Apr. 51–52
 accessories, Mar./Apr. 54
 Baumrucker, Mar./Apr. 53
 conversion to operating hysteroscope, Mar./Apr. 53
 development of, landmarks in, Mar./Apr. 52
 electrodes for, Mar./Apr. 52
 electrosurgical units for, Mar./Apr. 54
 endometrium
 ablation, Mar./Apr. 59
 resection, Mar./Apr. 59
 in hysteroscopic surgery (*see* Hysteroscopic surgery with resectoscope)

telescopes for, Mar./Apr. 52-53
uses of, Mar./Apr. 56
working element, Mar./Apr. 52

S

Sodium: plasma, after intrauterine surgery, Mar./Apr. 61
Squamous intraepithelial lesion and Bethesda system
(see Bethesda, system, squamous intraepithelial lesions)
Surgery with resectoscope: equipment, Mar./Apr. 51-53

T

TBS (see Bethesda system)
Telescopes: for resectoscope, Mar./Apr. 52-53
Training: for hysteroscopic surgery with resectoscope,
Mar./Apr. 63-64

Tumor

breast, benign, Jan./Feb. 13-14
cervix (see Cervix, tumor)
gestational trophoblastic, staging, Nov./Dec. 262, 266

U

Ultrasound

of breast lesions, Jan./Feb. 17

Urethra

closure pressure, May/June 117
closure pressure profiles, May/June 141-143
cough, May/June 143
resting, May/June 141
cross section, May/June 118, 119
mobility assessment, May/June 127-128

Urethrocystometry

in detrusor instability, May/June 140
in incontinence, May/June 139-141

Urethroscopy: in incontinence, May/June 130-131

Uroflowmetry

in incontinence, May/June 128-129
normal, in detrusor instability, May/June 128

Urology drainage pouch: placement of, Mar./Apr. 55

Uterus

corpus carcinoma

staging, Nov./Dec. 265-266
surgical staging, Nov./Dec. 261
myoma, resection, Mar./Apr. 56-57
polyps, resection, Mar./Apr. 56-57
resection, Mar./Apr. 56-57
septa, resection, Mar./Apr. 57
surgery, glycine and sodium absorption at, Mar./Apr.
61

V

Vagina: cross section, May/June 118, 119

Videocystourethrography: in incontinence, May/June
146

Viruses, papillomavirus (see Papillomavirus)

Voiding pressure studies: in incontinence, May/June
144-146

Vulvar carcinoma

staging, Nov./Dec. 266
TNM classification, Nov./Dec. 261
TNM classification and clinical staging, Nov./Dec. 259

W

Water: manometric water cystometer, May/June 132